Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

References

• Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956–3964. doi:10.1210/jc.2012-156322893714
   PubMed Web of Science ®Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14. doi:10.1016/s0021-9150(02)00330-112732381
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a. doi:10.1093/eurheartj/eht27323956253
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344. doi:10.1016/j.atherosclerosis.2016.08.01827594540
   PubMed Web of Science ®Google Scholar
• Chiou KR, Charng MJ. Genetic diagnosis of familial hypercholesterolemia in Han Chinese. J Clin Lipidol. 2016;10(3):490–496. doi:10.1016/j.jacl.2016.01.00927206935
   PubMed Web of Science ®Google Scholar
• Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013;24(4):288–294. doi:10.1097/MOL.0b013e32836308bc23839331
   PubMed Web of Science ®Google Scholar
• Pang J, Chan DC, Hu M, et al. Comparative aspects of the care of familial hypercholesterolemia in the “Ten Countries Study”. J Clin Lipidol. 2019;13(2):287–300. doi:10.1016/j.jacl.2019.01.00930797720
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa161566428304224
   PubMed Web of Science ®Google Scholar
• Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–2120. doi:10.1161/CIRCULATIONAHA.113.00467824014831
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341–350. doi:10.1016/S0140-6736(14)61374-X25282520
   PubMed Web of Science ®Google Scholar
• Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5(4):280–290. doi:10.1016/S2213-8587(17)30044-X28215937
   PubMed Web of Science ®Google Scholar
• Santos RD, Hovingh GK, Blom D, et al. Long-term evolocumab treatment in homozygous and severe heterozygous familial hypercholesterolemia: the TAUSSIG trial. J Am Coll Cardiol. 2019;73(9 Suppl 1):1715. doi:10.1016/S0735-1097(19)32321-6
   Web of Science ®Google Scholar
• Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk–primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073–1082. doi:10.1253/circj.cj-14-013024662398
   PubMed Web of Science ®Google Scholar
• Hirayama A, Yamashita S, Inomata H, et al. One-year efficacy and safety of evolocumab in Japanese patients - a pooled analysis from the open-label extension OSLER studies. Circ J. 2017;81(7):1029–1035. doi:10.1253/circj.CJ-16-101628367845
   PubMed Web of Science ®Google Scholar
• Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial. Diabetes Obes Metab. 2019;21(6):1455–1463. doi:10.1111/dom.1368030821053
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan Z, Lu J, et al. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: pre-specified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab. 2019;21(6):1464–1473. doi:10.1111/dom.1370030851062
   PubMed Web of Science ®Google Scholar
• Keech AC, Sever PS, Jiang L, et al. Efficacy and safety of long-term evolocumab use in Asian versus other subjects: the FOURIER trial. J Am Coll Cardiol. 2019;73(9 Suppl 1):189. doi:10.1016/S0735-1097(19)30797-1
   Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340. doi:10.1016/S0140-6736(14)61399-425282519
   PubMed Web of Science ®Google Scholar
• Jiang L, Sun LY, Dai YF, Yang SW, Zhang F, Wang LY. The distribution and characteristics of LDL receptor mutations in China: a systematic review. Sci Rep. 2015;5:17272. doi:10.1038/srep1727226608663
   PubMed Web of Science ®Google Scholar
• Peng J, Wu X, Wang S, et al. Familial hypercholesterolemia in China half a century: a review of published literature. Atheroscler Suppl. 2019;36:12–18. doi:10.1016/j.atherosclerosissup.2019.01.00330876527
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng Q, Zhang M, Lu H. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations. Br J Clin Pharmacol. 2019;85(1):114–125. doi:10.1111/bcp.1376730225890
   PubMed Web of Science ®Google Scholar